Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma
Thomas Powles(Queen Mary University of London), Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center), Nicole N. Davarpanah(La Roche College), Daniel Castellano(Universidad Complutense de Madrid), Petros Grivas(Seattle Cancer Care Alliance), Maha Hussain(Northwestern University), Siamak Daneshmand(Unknown), Corey Carter(La Roche College), Zoe J. Assaf(Natera (United States)), Himanshu Sethi(Natera (United States)), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Alexey Aleshin(Natera (United States)), Jürgen E. Gschwend(Institut für Arbeitsmarkt und Berufsforschung), Peter Albers(Düsseldorf University Hospital), Hiroyuki Nishiyama(University of Tsukuba), Joaquim Bellmunt(Dana-Farber Cancer Institute), Viraj Degaonkar(La Roche College), Shruti Sharma(Natera (United States)), Yi Shi(Huzhou University)
Cited by 128
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k